Compounded Semaglutide Ban: Where the FDA Stands in 2026

Published July 13, 2026. Updated October 14, 2026 with the August 2026 federal appeals court ruling and the current status of the FDA's 503B proposal.

The short answer: as of October 14, 2026, the FDA has not finalized a ban on compounded semaglutide or tirzepatide. Its proposal not to add semaglutide, tirzepatide, and liraglutide to the list of bulk ingredients that 503B outsourcing facilities may compound from is still pending, and no final decision has been published in the Federal Register. The national shortages that allowed widespread compounding were declared over in December 2024 (tirzepatide) and February 2025 (semaglutide), and on August 27, 2026 a federal appeals court upheld both of those decisions. Since the shortages ended, pharmacies generally can't compound what the FDA calls "essentially copies" of an approved drug. The main exception, at a traditional 503A pharmacy, requires a prescriber to document a change that makes a significant difference for that specific patient.

You finally found a version of semaglutide you could afford. The food noise quieted down, the scale started moving, and then the headlines showed up: the FDA wants to ban compounded semaglutide. Now you're somewhere between "should I stockpile" and "is my medication even legal," and the company selling it to you isn't rushing to explain.

This is the plain-English version. What the FDA actually proposed, what changed in June, what happens after July 30, and what to do if you're taking a compounded GLP-1 right now.

What Is the 2026 Compounded GLP-1 Ban Update?

On April 30, 2026, the FDA proposed not to add semaglutide, tirzepatide, and liraglutide to the list of bulk ingredients that large compounding facilities (called 503B outsourcing facilities) may compound from, and the notice was published in the Federal Register on May 1. On June 26, the agency extended the public comment deadline on that proposal from June 30 to July 30, 2026, after industry groups argued the original window didn't give them enough time to respond. They asked for 60 extra days. The FDA gave them 30.

That extension is the only thing that changed. The direction has not. Compounded semaglutide isn't banned outright, but copies of the approved drug have been restricted since the shortage ended, and the room left is narrowing.

What a 503B Facility Is, in Plain English

Federal law recognizes two kinds of compounding pharmacies. A traditional compounding pharmacy (503A) mixes a medication for one specific patient with one specific prescription, the way a pharmacist might prepare a custom dose for someone allergic to a filler ingredient. A 503B outsourcing facility is a different animal. It produces large batches of a drug without patient-specific prescriptions and ships them out at scale.

That large-batch model is what made cheap telehealth semaglutide subscriptions possible in the first place. A pharmacy filling one prescription at a time can't supply tens of thousands of subscribers. The FDA's proposal would formally keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list, which shuts the door on that factory-scale route outside of a shortage.

The agency also clarified in April 2026 that compounders can't sell what amounts to a copy of a commercially available drug in the same or similar strength. Taken together, the message to the compounded GLP-1 industry is hard to misread.

Is Compounded Semaglutide Still Legal in 2026?

It isn't banned outright, but the legal room to make it is much narrower than it was in 2024, and it depends on which kind of pharmacy is doing the compounding.

A 503A pharmacy compounds for individual patients with individual prescriptions. Under federal law it can't regularly compound drugs that are "essentially copies" of a commercially available drug. In its April 1, 2026 statement, the FDA explained that it treats a compounded drug as essentially a copy when it has the same active ingredient in the same, similar, or an easily substitutable strength, and the approved product can be given the same way. The exception is when "a prescriber determines and documents the compounded drug product contains a change that produces a significant difference" for an identified patient.

A 503B outsourcing facility makes large batches without patient-specific prescriptions. These facilities can't make a drug that is "essentially a copy of one or more FDA-approved drugs" unless that drug is on the FDA's shortage list, and semaglutide and tirzepatide came off that list in 2024 and 2025. The pending proposal would formally decide that semaglutide, tirzepatide, and liraglutide will not be added to the 503B bulks list, so outsourcing facilities could not compound them from bulk ingredients unless the drug was on the FDA's shortage list.

Ordering online doesn't change any of this. A telehealth company still needs a licensed prescriber and a pharmacy to fill the prescription, and the same rules apply to that pharmacy whether you found it through an app or down the street. That's why the two red flags further down this page matter: a seller claiming its product is the same as Wegovy or Ozempic, and a seller that won't name the pharmacy.

Legal status and safety are separate questions. As of May 31, 2026, the FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and the agency says these are likely underreported; we cover them in FDA's adverse event reports and warning letters on compounded GLP-1s.

The Shortage Is Over, and a Federal Court Agreed

Compounded GLP-1s became widely available because the brand-name drugs were on the FDA's shortage list, and federal law gives compounders more room while a drug is in shortage. That window has closed. The FDA determined the tirzepatide injection shortage was resolved on December 19, 2024, and announced the semaglutide shortage was resolved on February 21, 2025. The wind-down periods the agency gave compounders after those decisions ended between March and May 2025.

Compounders challenged both decisions in court. On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed the lower court in both cases (Outsourcing Facilities Association v. FDA, No. 25-10600 for tirzepatide and No. 25-10758 for semaglutide). The court held that any error in the FDA skipping notice and comment was harmless and that the agency's decision was not arbitrary or capricious. The semaglutide opinion is marked as not designated for publication, so it decides that case without setting circuit precedent.

The shortage route is already closed, and a court has upheld that. The separate 503B bulk-ingredient exclusion is still a proposal, and nothing changes under it until the FDA publishes a final decision.

The Pressure Has Been Building for a While

The July 30 deadline is one date in a longer sequence:

• December 2024 and February 2025: the FDA declares the tirzepatide and then the semaglutide shortage resolved, starting the clock on the end of shortage-era compounding.
• September 2025: the FDA sends a wave of warning letters to telehealth companies over misleading compounded GLP-1 marketing.
• February 2026: the FDA Commissioner announces targeted enforcement on compounded GLP-1s, naming misleading advertising, unauthorized importation, and pharmacies shipping more than 20 out-of-state prescriptions.
• March 2026: roughly 30 more warning letters go out.
• April 2026: the agency clarifies that compounders can't sell what is essentially a copy of a commercially available drug.
• April 30, 2026: the FDA announces the 503B exclusion proposal (published in the Federal Register May 1), the one with the July 30 comment deadline.
• June 2026: a third wave of 25 warning letters lands during the week of June 15, again citing claims that a compounded product is the "same" as the FDA-approved drug, plus marketing that never discloses which pharmacy actually made it. We go through those letters, and a September 2026 letter about GLP-1s compounded with added vitamins, in what the FDA warnings mean for compounded semaglutide.
• July 30, 2026: the extended comment period on the 503B proposal closes.
• August 27, 2026: the Fifth Circuit upholds the FDA's decisions that the tirzepatide and semaglutide shortages are over.
• October 2026: no final decision on the 503B proposal has been published.

Three waves of warning letters in under a year. That's an enforcement pattern, and it's aimed squarely at the compounded GLP-1 business model. (For background on how these medications work in the first place, our GLP-1 medications guide covers the basics.)

Is Compounded Semaglutide the Same as Wegovy or Ozempic?

No. The FDA has repeatedly cited the claim that a compounded product is the same as Wegovy or Ozempic as misleading marketing, and it named that exact wording in its 2026 warning letters. In April 2026 the agency clarified that compounders cannot sell what amounts to a copy of a commercially available drug in the same or similar strength. If your supplier tells you its compounded semaglutide is identical to the brand-name version, treat that as one of the red flags the FDA keeps flagging.

What Happens to Compounded Semaglutide After the FDA Deadline?

The comment period closed on July 30, 2026. The FDA reviews what came in, and the agency decides when to finalize the rule. As of this update it has not issued a final determination, and no date for that decision has been published. Once it is final, the three drugs stay off the 503B bulks list, so outsourcing facilities could compound them from bulk ingredients only while a drug is on the FDA's shortage list.

Could the comments change the outcome? In theory. In practice, the FDA granted half the extension industry asked for, and nothing in the June notice suggests the agency is rethinking its position. Patients who plan for the rule to be finalized will be in far better shape than the ones waiting on a reprieve.

If You're Taking Compounded Semaglutide Right Now

First, nothing changed on July 31. The rule isn't final, your medication did not become contraband at midnight, and panic-buying six months of vials is the wrong move. Stockpiling multidose vials means self-managing doses for months with nobody checking your response, and that's exactly where compounded GLP-1s have gone wrong for people.

Some of the adverse event reports the FDA has logged for compounded GLP-1s trace back to dosing errors, patients drawing the wrong amount from a multidose vial. Sophia Viner, DNP, APRN, FMCP-M, who leads weight loss care at Med Matrix, points to the delivery method itself as the difference: an FDA-approved pen delivers a fixed, pre-measured dose, while a vial and syringe leave the math to whoever is holding the needle at home.

Second, look hard at your current supplier. Two red flags come straight from the FDA's warning letters. If the company claims its product is the same as Wegovy or Ozempic, that's the exact claim the agency keeps citing as misleading. And if you can't find out which pharmacy compounds your medication, that's the other one. A company that won't name the pharmacy making your drug is telling you something.

Third, start the transition conversation now, while it's still a choice instead of an emergency. Switching from a compounded vial to an FDA-approved medication is a clinical decision. Doses don't always map one-to-one, and bloodwork should confirm where your metabolic markers actually stand before anything changes. That's a provider conversation, and it's exactly what a free discovery call is for.

Your Options Are Better Than They Were a Year Ago

The main reason compounded semaglutide took off was price. That gap has narrowed.

On the injectable side, brand-name semaglutide and tirzepatide are both FDA-approved for weight management, and choosing between them should come down to your labs and health history rather than marketing. Our semaglutide vs tirzepatide comparison walks through how the two differ, and if you're already mid-treatment, we've covered switching between them safely.

There's also a pill now. Oral Wegovy, approved December 22, 2025, runs $149 a month without insurance, and trial participants lost about 17 percent of their body weight compared with 2.7 percent on placebo. For anyone who only chose compounded vials to avoid a four-figure monthly pen, that changes the math considerably. We compared the two formats in GLP-1 pills vs injections and broke down real-world pricing in our tirzepatide cost guide.

The Difference Between a Prescription and a Program

A mail-order compounder makes money when you stay subscribed. A medical weight loss program gets judged on whether your body actually changes, and that difference shows up before the first injection ever happens.

In our clinic, nobody starts semaglutide without an 80+ biomarker panel first. Weight that won't move usually has company: a thyroid or adrenal problem, insulin resistance, or a hormone imbalance that no appetite medication will fix on its own. Left unmeasured, those are the reasons weight comes back the day the medication stops. Treating them alongside GLP-1 therapy is the whole point of a functional medicine approach to weight.

Body composition gets tracked too, on an InBody 770 scan at every visit, because weight loss that's half muscle is a bad trade. Muscle loss during rapid weight loss is preventable, which is why Sophia Viner, DNP, APRN, FMCP-M, builds protein targets and strength training guidance into weight loss protocols from day one.

And the medication itself is FDA-approved semaglutide or tirzepatide, dispensed the regulated way. When the 503B rule is finalized, whenever that happens, nothing about our patients' supply changes.

How Semaglutide Works at Med Matrix, Start to Finish

Whether you're on a compounded version and want a real transition plan, or you're starting from zero, every patient goes through the same five steps.

It begins with a free discovery call with a patient coordinator to talk through your goals and figure out whether the semaglutide program or one of our other weight loss treatments fits your situation. Then comes testing: the 80+ biomarker panel, a full body composition scan, and in-depth health questionnaires. The medical team reviews everything together, cross-referencing your symptoms against your lab patterns, before you sit down for a full 60-minute consultation with your provider to go over every result and build the plan. After that comes the part telehealth compounders skip entirely: ongoing support, with dose adjustments, repeat scans, and direct access to your care team as your body responds.

Onboarding runs $1,500 all-in, covering labs, the scan, provider prep, and the hour-long consultation. New patients get a $100 voucher toward the first visit, and HSA and FSA cards are accepted.

Frequently Asked Questions

Is compounded semaglutide banned right now?

No. The FDA's 503B exclusion is still a proposal. The public comment period on that proposal closed on July 30, 2026, and as of this update the agency has not issued a final determination. The rule only takes effect once the agency finalizes it. Compounded semaglutide isn't banned outright, but since the shortage ended, pharmacies are restricted from compounding copies of the approved drug, and the FDA's push toward ending large-scale compounding of it has been consistent since April 2026.

Is compounded semaglutide still legal to get online in 2026?

It isn't banned, but buying it online doesn't change the rules the pharmacy has to follow. Since the shortage ended, a 503A pharmacy generally can't compound what the FDA calls "essentially copies" of an approved drug unless a prescriber documents a change that makes a significant difference for that specific patient, and a 503B facility generally can't make copies of an approved drug that isn't in shortage. Ask the company which pharmacy fills your prescription.

Will compounded semaglutide be banned?

Not yet. The shortage-era route to widespread compounding closed in February 2025, and a federal appeals court upheld that decision on August 27, 2026. The FDA's separate proposal to keep semaglutide off the 503B bulk ingredients list is still pending, and as of October 14, 2026 no final decision has been published.

Is compounded tirzepatide banned in 2026?

There's no outright ban. The FDA declared the tirzepatide shortage resolved in December 2024, the wind-down period for compounders ended in March 2025, and the Fifth Circuit upheld the FDA's decision on August 27, 2026. Tirzepatide is also one of the three drugs in the pending 503B proposal, which has not been finalized.

What happened to compounded semaglutide after the shortage ended?

The FDA gave compounders a wind-down period after it declared the semaglutide shortage resolved on February 21, 2025. That period ended in April 2025 for 503A pharmacies and on May 22, 2025 for 503B outsourcing facilities. After that, the FDA's limits on compounding copies of approved drugs applied again in full.

Did I have to stop taking compounded semaglutide on July 30?

No. July 30 was the deadline for public comments, not a shutdown date, and nothing about your medication changed that day. What the date should change is your timeline: the window to plan a transition on your own schedule, with labs and a provider involved, is open now and will feel much shorter once the rule is finalized.

Is compounded semaglutide dangerous?

It carries risks the FDA-approved versions don't. Compounded drugs aren't reviewed by the FDA for safety or effectiveness before they're sold, and the agency had received 990 adverse event reports linked to compounded semaglutide as of May 31, 2026, some involving dosing errors from multidose vials. Plenty of doses go fine. The problem is what's missing: FDA review of the product, and anyone monitoring how your body responds to it.

What should I ask my current semaglutide supplier?

Two questions. Which pharmacy compounds the medication, and what their plan is if the FDA finalizes the 503B exclusion. If you can't get a straight answer to the first, or any answer to the second, take that seriously. The FDA's June 2026 warning letters specifically cited companies that never disclose the compounding pharmacy's identity.

Does any of this affect Med Matrix patients?

No. Our weight loss program has always used FDA-approved semaglutide and tirzepatide, so the 503B rule doesn't touch our patients' supply. What it will change is the number of people looking for a new home for their weight loss care over the next year, and the program was built for exactly that kind of handoff: labs first, then medication, then monitoring.

If you're on compounded semaglutide and you'd rather have a plan than a surprise, we'll run the labs, look at where your health actually stands, and map the transition with you. Start Feeling Like Yourself Again with a program built to outlast the rule change.